Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sapropterin dihydrochloride

- PMLiVE

The Orkambi blame game

Grilling by MPs sheds some light on long-running row over CF drug

- PMLiVE

#OrkambiNow?

After a long standoff over CF treatment Orkambi, is a deal imminent?

- PMLiVE

Leader named for NHS digital transformation unit, but scepticism persists

NHS managers question logic of another authority

- PMLiVE

Is Orkambi deal close? Vertex meets again today with NHS England

Campaigners hopes rise after three year wait

- PMLiVE

Optimism on Orkambi in England as talks to resume

Scotland's deal puts pressure on NHS England and NICE

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

- PMLiVE

NHS England’s medicines chief: stop ‘salami slicing’ and get faster market access

Pressure will be maintained on costs, despite VPAS price cap deal

- PMLiVE

BioMarin prepares for haemophilia A gene therapy data readout, filing

Key long-term data expected in July

- PMLiVE

Greater Manchester backs move to outcome-based payment

Region teams up with Cancer Research UK to accelerate change

- PMLiVE

UK patient activist group takes aim at Orkambi patent

Calls to bypass patent adds to pressure on Vertex

- PMLiVE

Vertex an “extreme outlier” in pricing and behaviour, says NHS England

Members of parliament aim to break three year deadlock

- PMLiVE

NHS England sees off AbbVie’s Hep C legal challenge

Claims of unfair process dismissed by High Court

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links